Progesterone aqueous solution type injection as well as preparation method and drug delivery system thereof
By using phosphate buffering system and β-cyclodextrin inclusions in aqueous progesterone injections, combined with constant speed subcutaneous administration, the stability and blood drug concentration of progesterone injections were solved, and high safety was achieved Sex and stability avoid painful reactions and side effects of injections.
Patent Information
- Application Number
- CN202310551909.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
The existing progesterone aqueous solution injection has poor stability and is difficult to achieve a low steady-state blood drug concentration level. It also has a large pain response, strong irritation, easy to allergize, and can easily cause the drug to accumulate local muscle tissue and cause lumps and pain. side effect.
Using phosphate buffering system as pH regulator, β-cyclodextrin and progesterone form an inclusion compound, and the drug is administered in batches through a constant-speed subcutaneous dosage device to reduce the total dosage and maintain a low effective steady-state blood. Drug concentration and improve the solubility and stability of progesterone through β-cyclodextrin compounds.
Improve the stability and safety of progesterone aqueous solution injection, avoid painful reactions and side effects during injection, realize the possibility of storage at room temperature, significantly reduce the fluctuation range of blood drug concentration, and enhance the use of drugs. Security.
Smart Images

Figure CN118986866A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a progesterone aqueous solution injection and a preparation method and a drug delivery system thereof. Background Art
[0002] Progesterone is a natural progestin and a commonly used sex hormone drug. It has the function of regulating hormone balance and the general effect of progestin. It is widely used in clinical practice, mainly for the treatment of menstrual disorders (such as functional uterine bleeding with amenorrhea), progesterone deficiency, threatened abortion and habitual abortion, and premenstrual tension syndrome. It is used with estrogen cycles to counteract the effects of estrogen alone on the endometrium.
[0003] Progesterone is a fat-soluble substance, insoluble in water, but soluble in organic solvents such as ethanol. Progesterone is rapidly destroyed in the gastrointestinal tract and liver after oral administration. In addition to oral administration, there are two main routes of administration on the market: vaginal administration and injection. More than 90% of progesterone in plasma is bound to proteins, and only 3% is free. Its metabolites are mainly bound to glucuronic acid and excreted in the urine. Currently, the most common progesterone aqueous solution injection is an oil needle injection. This type of injection has a large pain reaction during injection, is highly irritating, and is prone to allergies. It is also easy to cause drug accumulation in local muscle tissue, causing lumps and pain, etc., which brings troubles to patients, especially long-term users. The progesterone aqueous solution injection that has been on the market also has the problem of poor stability and difficulty in achieving a low steady-state blood drug concentration level.
[0004] Chinese patent CN101152186A uses progesterone to prepare submicroemulsion, and then prepares progesterone aqueous solution injection. This method improves the pain and allergy of traditional oil injection to a certain extent, and also has less irritation and long-term use tolerance, but the pain is still stronger than water injection, and the types of excipients used in the preparation process are more, and the processes of water phase and oil phase preparation, heating homogenization and cooling dilution are added, and the process is cumbersome. European patent EP1637167B1 uses hydroxypropyl-β-cyclodextrin as a solubilizing agent. When the dosage reaches 12% to 55%, the solubility of progesterone in water can be increased, and then a progesterone aqueous solution injection is prepared. The patent also reports that in order to achieve its solubilizing effect on progesterone, the optimal dosage of hydroxypropyl-β-cyclodextrin in the prescription is 48%, but the FDA maximum excipient usage limit is 40% (w / w), so its use needs to be particularly cautious.
[0005] The progesterone injection solution that has been launched on the market has the following trade names: The specification is 1.112mL:25mg. It is used for subcutaneous one-time administration. The human pharmacokinetic parameters after administration are shown in Table 1.
[0006] Table 1 Single subcutaneous injection of 25 mg, 50 mg, 100 mg PK parameters after
[0007] PK parameters 25mg 50mg 100mg <![CDATA[C max (ng / mL)]]> 54.7±13.1 115.3±26.6 249.9±67.0 <![CDATA[T max (h)]]> 0.9±0.4 0.9±0.4 0.9±0.4 <![CDATA[AUC 0-t (ng / mL / h)]]> 441.5±92.9 978.8±341.4 1683.2±240.1 <![CDATA[AUC 0-∞ (ng / mL / h)]]> 521.2±113.0 1103.8±438.4 1771.1±247.4 <![CDATA[%AUC extra ]]> 14.9±6.7 10.6±5.3 5.0±2.3 <![CDATA[t 1 / 2 (h)]]> 41.3±17.9 39.2±17.8 27.3±9.4 MRT(h) 43.4±15.0 35.8±11.9 23.2±4.9
[0008] The above parameters show that a single subcutaneous administration of 25 mg of progesterone injection solution resulted in a blood concentration of 54.7 ± 13.1 ng / mL, and 50 mg and 100 mg of C max It is dose-dependent. This value is much larger than the C of traditional progesterone oil injection preparations. max Value (7ng / mL). max If the value is too high, it may bring risks to medication.
[0009] Therefore, there is an urgent need to develop a progesterone preparation that can maintain a low effective steady-state blood drug concentration level while reducing the side effects of existing progesterone oil injection preparations, such as large pain reaction, high irritation, easy allergy, and easy drug accumulation in local muscle tissue causing lumps and pain. Summary of the invention
[0010] The technical problem to be solved by the present invention is to overcome the defects of poor stability and difficulty in achieving a low steady-state blood drug concentration level of progesterone aqueous solution injection in the prior art, and provide a progesterone aqueous solution injection and its preparation method and drug delivery system. The present invention administers the progesterone aqueous solution injection through a constant-rate subcutaneous drug delivery device, which can not only reduce the total progesterone dosage, but also maintain the progesterone at a low level of effective steady-state blood drug concentration, greatly increasing the safety of the drug; at the same time, the present invention uses a phosphate buffer system as a pH regulator, and forms an inclusion complex with β-cyclodextrin and progesterone, which solves the solubility of progesterone in water and improves stability; the obtained progesterone aqueous solution injection has high safety, stable properties, no pain reaction during injection and is easy to store.
[0011] The present invention solves the above technical problems through the following technical solutions.
[0012] The present invention provides a progesterone aqueous solution injection, which comprises progesterone, a β-cyclodextrin compound, a pH regulator and water for injection;
[0013] Wherein, the mass ratio of the progesterone to the β-cyclodextrin compound is 1:(15-40); and the pH regulator is a phosphate buffer system.
[0014] In the present invention, the β-cyclodextrin compound can be one or more of β-cyclodextrin, methyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and sulfobutyl-β-cyclodextrin sodium, such as sulfobutyl-β-cyclodextrin. Since progesterone is a poorly soluble drug, the present invention can increase the solubility of progesterone by encapsulating it in the hollow structure of the β-cyclodextrin compound, so that it can maintain a stable molecular state in a solution of a certain concentration.
[0015] In the present invention, the mass ratio of the progesterone to the β-cyclodextrin compound is preferably 1:(15-20), such as 1:15 or 1:20.
[0016] In the present invention, the content of the β-cyclodextrin compound can be 15-40% (w / v), preferably 15-20% (w / v), for example 15% (w / v) or 20% (w / v), where % (w / v) is the mass volume ratio of the β-cyclodextrin compound to the progesterone aqueous solution injection.
[0017] In the present invention, the pH adjuster is preferably a "sodium dihydrogen phosphate and disodium hydrogen phosphate" buffer system.
[0018] The mass ratio of the sodium dihydrogen phosphate to the sodium hydrogen phosphate can be 1:(1-10), preferably 1:(2-6), for example 1:3.85. The above mass ratio is related to the buffering capacity and has a certain influence on the stability of the system.
[0019] In the present invention, the pH value of the progesterone aqueous solution injection may range from 6.0 to 8.0, preferably from 6.0 to 7.15.
[0020] In the present invention, preferably, the encapsulation rate of progesterone in the progesterone aqueous solution injection is not less than 98%, more preferably 99.8%, where % refers to the mass percentage of the encapsulated progesterone to the progesterone in the progesterone aqueous solution injection.
[0021] The present invention also provides a method for preparing the above-mentioned progesterone aqueous solution injection, which comprises the following steps: mixing the various components of the progesterone aqueous solution injection.
[0022] In the present invention, the preparation method preferably comprises: dissolving the phosphate buffer system in the water for injection, adding the β-cyclodextrin compound to dissolve, and then adding progesterone to dissolve to obtain a progesterone aqueous solution injection.
[0023] The dissolution temperature of the β-cyclodextrin compound may be 25 to 70°C, preferably 30 to 50°C.
[0024] The dissolution temperature of the progesterone may be 30-90°C, preferably 40-80°C, such as 60°C or 70°C.
[0025] In the present invention, the mixing may further include post-processing operations of "volume setting, filtration, filling and sealing".
[0026] Wherein, the filtration adopts a syringe filter.
[0027] Preferably, the filtration is sterile filtration, which can not only remove insoluble impurities but also remove bacterial colonies to achieve sterility requirements.
[0028] The type and pore size of the filter membrane used for the sterile filtration can be determined by a filter membrane screening test. The type of the filter membrane is preferably one or more of PES, PVDF, PTFE, cellulose ester filter membrane, polyamide filter membrane and polysulfone filter membrane, such as PES or PVDF. The pore size is preferably 0.20 to 1 μm, such as 0.22 μm, 0.45 μm, 0.65 μm or 1 μm.
[0029] Wherein, the sealing may also include a sterilization operation.
[0030] Preferably, the sterilization is carried out by moist heat sterilization. Sterility and injection safety are ensured by enduring the terminal sterilization process. The sterilization temperature is preferably 115-125°C, for example, 121°C. The sterilization time is preferably 10-20 minutes, for example, 15 minutes. If the sterilization time is too short, the sterilization is not thorough; if the sterilization time is too long, the drug itself is damaged, affecting the stability of the progesterone aqueous solution injection.
[0031] In the present invention, preferably, the mixing further includes post-processing operations of "concentrating volume, sterile filtration, filling and sealing" or "concentrating volume, filtration, filling, sealing and sterilization".
[0032] The present invention also provides a method for storing the above-mentioned progesterone aqueous solution injection, which comprises: sealing the progesterone aqueous solution injection in a light-shielded manner at 2-40°C.
[0033] Those skilled in the art are aware that in order to maintain the stability of the progesterone aqueous solution injection, it is usually necessary to store it under refrigerated conditions, which requires more costs and processes. The progesterone aqueous solution injection of the present invention overcomes the above difficulties and can be stored not only under refrigerated conditions (2 to 8°C) but also at room temperature. The room temperature is preferably 25 to 40°C.
[0034] The present invention also provides a drug delivery system, which comprises the above-mentioned progesterone aqueous solution injection and a constant-rate subcutaneous drug delivery device; the drug delivery device is used for delivering the progesterone aqueous solution injection.
[0035] In the present invention, the constant rate subcutaneous drug delivery device may include a drug delivery pump and a drug delivery controller.
[0036] In the present invention, the constant speed subcutaneous drug delivery device can be an insulin injection device. The present invention can use the insulin injection pump disclosed in Chinese patent CN307860695S as the constant speed subcutaneous drug delivery device.
[0037] In the present invention, the progesterone aqueous solution injection is administered subcutaneously in small amounts in divided doses through the constant-rate subcutaneous drug delivery device, so that the drug can maintain a steady-state blood drug concentration during the medication period.
[0038] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0039] The reagents and raw materials used in the present invention are commercially available.
[0040] The positive and progressive effects of the present invention are:
[0041] The present invention administers the progesterone aqueous solution injection in divided doses through a constant-rate subcutaneous drug delivery device. Compared with the traditional administration method, it can not only reduce the total progesterone administration dose, but also maintain the effective steady-state blood drug concentration of progesterone at a lower level, thereby greatly increasing the safety of drug use.
[0042] At the same time, the present invention uses a phosphate buffer system as a pH regulator, forms an inclusion compound with a beta-cyclodextrin compound and progesterone, achieves the purpose of solubilization, solves the solubility of progesterone in water, and ensures the stability problem of the active ingredient being easily degraded under acid and alkaline conditions, thereby preparing a progesterone aqueous solution injection with high safety, stable properties, no pain reaction during injection and easy storage, and avoids the problems of high irritation and many side effects of the progesterone oil solution injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 This is a graph showing the changes in impurities in the aqueous solution of progesterone injection in Example 1 after being placed at 60±2°C for 8 weeks.
[0044] Figure 2 This is a graph showing the changes in impurities in the aqueous solution of progesterone injection in Example 2 after being placed at 60±2°C for 8 weeks.
[0045] Figure 3 This is the average drug-time curve of the progesterone aqueous solution injection in Example 4 in the plasma of SD rats after multiple combined subcutaneous injections.
[0046] Figure 4 This is the average drug-time curve of the progesterone aqueous solution injection in Example 5 after multiple combined subcutaneous injections in beagle dog plasma. DETAILED DESCRIPTION
[0047] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0048] The insulin used in the embodiments of the present invention adopts the insulin injection pump disclosed in Chinese patent CN307860695S as a constant-rate subcutaneous drug delivery device, which is purchased from Kailian Medical Technology (Shanghai) Co., Ltd.
[0049] Example 1 Progesterone aqueous solution injection (Specification: 2mL: 20mg)
[0050] Table 2 Prescription of progesterone aqueous solution injection
[0051] prescription Dosage Progesterone 10(g) Sulfonbutyl-β-cyclodextrin 150(g) Sodium dihydrogen phosphate monohydrate 0.265(g) Disodium hydrogen phosphate 1.02(g) Water for injection qs to 1000mL
[0052] Preparation process: Weigh the prescribed amount of sodium dihydrogen phosphate monohydrate and sodium dihydrogen phosphate, add 80% of the prescribed amount of water for injection, and after complete dissolution, add the prescribed amount of sulfobutyl-β-cyclodextrin, stir and dissolve completely, add progesterone, stir and dissolve at 70°C, add water for injection to 1000mL, filter with 0.45μm PES filter membrane, seal, and sterilize at 121°C for 15min. The pH value of the progesterone aqueous solution injection prepared by the prescription in Table 2 above is 6.0-7.15.
[0053] The stability of the preparation at 60±2℃ was investigated with content, encapsulation efficiency and impurities as test indicators. See Table 3 and Table 3 for details. Figure 1 .
[0054] Table 3 Stability results of progesterone aqueous solution injection at 60±2℃
[0055]
[0056] Note: The content in the table refers to the ratio of the actual detected concentration to the theoretical concentration. For example, if the theoretical concentration is 10 mg / mL and the actual detected concentration is 9.8 mg / mL, the content is 98%.
[0057] According to the results, the prepared progesterone aqueous solution injection was placed at 60±2°C for 8 weeks, and the content (96.5%) after 8 weeks decreased by 6.2% compared with the initial content (102.7%), and the total impurities (1.41%) after 8 weeks increased by 0.85% compared with the initial total impurities (0.56%), and the maximum single impurity and encapsulation rate were basically unchanged. The quality standard requires that the maximum single impurity content at a wavelength of 241nm shall not exceed 0.5% of the labeled amount of progesterone, and the total impurities shall not exceed 2.0%. It can be seen that the progesterone aqueous solution injection sample prepared in Example 1 meets the quality standards.
[0058] Example 2 Progesterone aqueous solution injection (Specification: 2mL: 20mg)
[0059] Table 4 Prescription of progesterone aqueous solution injection
[0060] prescription Dosage Progesterone 10(g) Sulfonbutyl-β-cyclodextrin 200(g) Sodium dihydrogen phosphate monohydrate 0.265(g) Disodium hydrogen phosphate 1.02(g) Water for injection qs to 1000mL
[0061] Preparation process: Weigh the prescribed amount of sodium dihydrogen phosphate monohydrate and sodium dihydrogen phosphate, add 80% of the prescribed amount of water for injection, and after complete dissolution, add the prescribed amount of sulfobutyl-β-cyclodextrin, stir and dissolve completely, add progesterone, stir and dissolve at 60°C, add water for injection to 1000mL, filter with 0.65μm PES filter membrane, seal, and sterilize at 121°C for 15min. The pH value of the progesterone aqueous solution injection prepared by the prescription in Table 4 above is 6.0-7.21.
[0062] The stability of the preparation at 60±2℃ was investigated with content, encapsulation efficiency and impurities as test indicators. See Table 5 and Table 5 for details. Figure 2 .
[0063] Table 5 Stability results of progesterone aqueous solution injection at 60±2℃
[0064]
[0065] Note: The content in the table refers to the ratio of the actual detected concentration to the theoretical concentration. For example, if the theoretical concentration is 10 mg / mL and the actual detected concentration is 9.8 mg / mL, the content is 98%.
[0066] According to the results, the prepared progesterone aqueous solution injection was placed at 60±2°C for 8 weeks, and the content (99.8%) after 8 weeks decreased by 4.0% compared with the initial content (103.8%), and the total impurities (1.14%) after 8 weeks increased by 0.60% compared with the initial total impurities (0.54%), and the maximum single impurity and encapsulation rate were basically unchanged. The quality standard requires that the maximum single impurity content at a wavelength of 241nm shall not exceed 0.5% of the labeled amount of progesterone, and the total impurities shall not exceed 2.0%. It can be seen that the progesterone aqueous solution injection sample prepared in Example 2 meets the quality standards.
[0067] Example 3 Progesterone aqueous solution injection (different drug loading ratios)
[0068] On the basis of Example 1, the mass ratio of progesterone to the β-cyclodextrin (hereinafter referred to as drug loading ratio) was changed. The results are shown in Table 6.
[0069] Table 6 Results of solutions prepared under different drug loading ratios
[0070]
[0071]
[0072] It can be seen from Table 6 that when the drug loading ratio is within the scope of the present invention, the obtained progesterone aqueous solution injection samples all meet the quality standards. When the drug loading ratio is 1:20, the dissolution time is the shortest, which is more conducive to the preparation process.
[0073] Example 4: Subcutaneous administration of progesterone aqueous solution injection to SD rats
[0074] A 2mL:20mg aqueous solution of progesterone injection was administered to SD rats. First, a single dose of 0.01mg / kg was administered, and plasma was collected at 0min, 4min, 8min, 19min, 30min and 1h; 1h later, the dosing pump was turned on and a single subcutaneous dose of 0.01mg / kg was administered. One group was administered every 1h, and each group was administered 12 times continuously, for a total of 5 groups, for a total of 60 times. Blood was collected at 2h, 3h, 4h, 5h, 6h and 7h to determine the blood drug concentration in SD rats.
[0075] Four SD rats were tested. The drug-time data and drug-time curves are shown in Tables 7 and Figure 3 .
[0076] Table 7 Drug-time data after multiple subcutaneous administration in male SD rats
[0077]
[0078] Note: "SD" in the table refers to standard deviation and "RSD" refers to relative standard deviation.
[0079] The results showed that through multiple subcutaneous administration, the blood drug concentration in the body was maintained within the blood drug concentration range of 1 to 7.5 ng / mL, with a smaller fluctuation range and higher safety. Progesterone can maintain a low and relatively steady-state blood drug concentration level in SD rats.
[0080] Example 5: Subcutaneous administration of progesterone aqueous solution injection to beagle dogs
[0081] The 2mL:20mg progesterone aqueous solution injection was administered to beagle dogs. The dosing pump was turned on and a single dose of 0.01mg / kg was administered (a dog weighs about 10kg, i.e. 0.1mg / dog). First, within the first hour, one group was administered every about 15min, and each group was administered 4 times continuously, for a total of 3 groups, and plasma was collected at 14min, 29min, and 59min; thereafter, one group was administered every 1.5h, and each group was administered 4 times continuously, for a total of 16 groups, and blood was collected at 2h, 4h, 6h, 8h, 10h, 24h, and 25.5h to determine the blood drug concentration in the beagle dogs.
[0082] Two beagle dogs were tested, and the drug-time data and drug-time curve are shown in Table 8 and Figure 4 .
[0083] Table 8 Individual and average drug-time curve data after multiple subcutaneous administration in male beagle dogs
[0084]
[0085] Note: "SD" in the table refers to standard deviation and "RSD" refers to relative standard deviation.
[0086] The results showed that through multiple subcutaneous administration, the blood drug concentration in the body was maintained within the blood drug concentration range of 4 to 25 ng / mL, with a smaller fluctuation range and higher safety. Progesterone can maintain a relatively steady-state blood drug concentration level in beagle dogs.
[0087] Example 6 Stability of Progesterone Aqueous Solution Injection under Different pH Conditions
[0088] On the basis of Example 1, the type of pH regulator was changed. Histidine salt buffers with pH values of 4.5±0.2, 5.5±0.2, and 6.5±0.2 (corresponding to numbers 1 to 3 in Table 9, respectively) and phosphate buffers with pH values of 7.5±0.2 and 8.5±0.2 (corresponding to numbers 4 and 5 in Table 9, respectively) were prepared. The effects of various pH conditions on the encapsulation efficiency, content, and related substances of the progesterone injection samples were investigated.
[0089] According to Table 9, the progesterone aqueous solution injection obtained by using phosphate buffer can maintain good stability at room temperature and is easy to store; while the progesterone aqueous solution injection obtained by using histidine buffer has poor stability.
[0090] Table 9 Stability of progesterone aqueous solution injection under different pH conditions
[0091]
[0092] In summary, the preparation provided by the present invention is simple and feasible to prepare, and is easy to scale up for industrial production. The stability study of the preparation showed that after being placed under high temperature conditions for 8 weeks, all indicators of the preparation met the quality research standards. And the pharmacokinetic data in SD rats and beagle dogs showed that after multiple subcutaneous administration, progesterone can maintain a low steady-state blood drug concentration level in the animal body.
Claims
1. A progesterone aqueous solution injection, It is characterized in that It includes progesterone, β-cyclodextrin compounds, pH regulators and water for injection; Wherein, the mass ratio of the progesterone to the β-cyclodextrin compound is 1:(15-40); and the pH regulator is a phosphate buffer system.
2. The progesterone aqueous solution injection according to claim 1, It is characterized in that The β-cyclodextrin compound is one or more of β-cyclodextrin, methyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin and sulfobutyl-β-cyclodextrin sodium, such as sulfobutyl-β-cyclodextrin; And / or, the mass ratio of the progesterone to the β-cyclodextrin compound is 1:(15-20), for example 1:15 or 1:20; And / or, the content of the β-cyclodextrin compound is 15-40% (w / v), preferably 15-20% (w / v), for example 15% (w / v) or 20% (w / v), where % (w / v) is the mass volume ratio of the β-cyclodextrin compound to the progesterone aqueous solution injection; And / or, the pH regulator is a "monobasic sodium phosphate and disodium hydrogen phosphate" buffer system; And / or, the pH value of the progesterone aqueous solution injection is in the range of 6.0 to 8.0, preferably 6.0 to 7.15; And / or, the encapsulation rate of progesterone in the progesterone aqueous solution injection is not less than 98%, preferably 99.8%, where % refers to the mass percentage of encapsulated progesterone to progesterone in the progesterone aqueous solution injection.
3. The progesterone aqueous solution injection according to claim 2, It is characterized in that The mass ratio of the sodium dihydrogen phosphate to the sodium hydrogen phosphate is 1:(1-10), preferably 1:(2-6), for example 1:3.
85.
4. A method for preparing the progesterone aqueous solution injection according to any one of claims 1 to 3, It is characterized in that It includes the following steps: The components of the progesterone aqueous solution injection are simply mixed.
5. The method for preparing the progesterone aqueous solution injection according to claim 4, It is characterized in that The preparation method comprises: dissolving the phosphate buffer system in the water for injection, adding the β-cyclodextrin compound to dissolve, and then adding progesterone to dissolve, so as to prepare a progesterone aqueous solution injection; And / or, after the mixing, the post-processing operations of "volume setting, filtration, filling and sealing" are also included.
6. The method for preparing the progesterone aqueous solution injection according to claim 5, It is characterized in that The dissolution temperature of the β-cyclodextrin compound is 25 to 70°C, preferably 30 to 50°C; and / or, the dissolution temperature of the progesterone is 30 to 90°C, preferably 40 to 80°C, for example 60°C or 70°C; And / or, the filtering adopts a syringe filter; And / or, the filtration is sterile filtration; The type of filter membrane used for sterile filtration is preferably one or more of PES, PVDF, PTFE, cellulose ester filter membrane, polyamide filter membrane and polysulfone filter membrane, such as PES or PVDF; the pore size of the filter membrane used for sterile filtration is preferably 0.20 to 1 μm, such as 0.22 μm, 0.45 μm, 0.65 μm or 1 μm; And / or, the sealing further includes a sterilization operation; preferably, the sterilization is carried out by moist heat sterilization; The sterilization temperature is preferably 115-125° C., such as 121° C.; the sterilization time is preferably 10-20 min, such as 15 min.
7. A method for storing the progesterone aqueous solution injection according to any one of claims 1 to 3, It is characterized in that It includes: The progesterone aqueous solution injection is sealed in a light-shielded state at 2-40°C.
8. The storage method of the progesterone aqueous solution injection according to claim 7, It is characterized in that The progesterone aqueous solution injection is sealed and shielded from light at 25-40°C.
9. A drug delivery system, It is characterized in that The invention comprises the progesterone aqueous solution injection according to any one of claims 1 to 3 and a constant-rate subcutaneous drug delivery device; the drug delivery device is used for delivering the progesterone aqueous solution injection.
10. The drug delivery system according to claim 9, It is characterized in that The constant-rate subcutaneous drug delivery device comprises a drug delivery pump and a drug delivery controller; And / or, the constant rate subcutaneous drug delivery device adopts an insulin injection device.
